Survodutide (Dual GLP-1/Glucagon Agonist) — Weight & Metabolism
Investigational dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH/NASH, developed by Boehringer Ingelheim.
Overview
Survodutide (BI 456906) is an investigational dual agonist peptide that activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma, survodutide represents a novel approach to obesity and metabolic disease by combining the appetite-suppressing and insulin-sensitizing effects of GLP-1 agonism with the energy expenditure-enhancing and hepatic lipid-reducing effects of glucagon agonism. In Phase 2 trials, survodutide demonstrated impressive weight loss of up to 18.7% at 46 weeks and significant improvements in liver fat content in patients with MASH (metabolic dysfunction-associated steatohepatitis). The glucagon component differentiates survodutide from pure GLP-1 agonists and dual GLP-1/GIP agonists like tirzepatide. Glucagon increases energy expenditure by stimulating hepatic lipid oxidation and thermogenesis, potentially providing metabolic benefits beyond weight loss alone. Phase 3 trials (SYNCHRONIZE program) are evaluating survodutide in obesity, MASH with fibrosis, and type 2 diabetes. If approved, survodutide would represent a new therapeutic class for obesity with a distinct mechanism from existing GLP-1 based therapies.
Indications
- Investigational: Obesity and overweight (Phase 3)
- Investigational: MASH/NASH with liver fibrosis (Phase 3)
- Investigational: Type 2 diabetes mellitus (Phase 2)
Mechanism of Action
Activates GLP-1 receptors in the hypothalamus (appetite suppression) and pancreas (glucose-dependent insulin secretion)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Survodutide | 0.3 mg | Once weekly (starting dose) | Titration starting dose from Phase 2 trials |
| Survodutide | 2.4 mg | Once weekly | Moderate dose — Phase 2 efficacy demonstrated |
| Survodutide | 4.8 mg | Once weekly | Highest Phase 2 dose — maximum weight loss observed |
Evidence Grade
GRADE C
Safety & Contraindications
- GI side effects: nausea (40-60%), vomiting, diarrhea — consistent with GLP-1 class
- Dose-dependent GI tolerability — requires slow titration
- Heart rate increase observed (glucagon component contribution)
- Hyperglycemia potential from glucagon agonism (mitigated by GLP-1 component)
- Hypoglycemia possible when combined with insulin or sulfonylureas
- Not yet approved — all safety data from clinical trials with limited long-term follow-up
- Potential for cholelithiasis (gallstones) with rapid weight loss